Susan E. Bates, MD

Closed
Call
Website

Photos

161 Fort Washington Ave Fl 9
New York, NY 10032
+1 (212) 305-5098
https://doctors.columbia.edu
Dr. Susan Bates received her M.D. degree from the University of Arkansas School of Medicine. She completed her clinical training in internal medicine at Georgetown University in Washington, D.C., and in medical oncology at the National Cancer Institute (NCI) in Bethesda, MD. Dr. Bates was a Lead Clinical Investigator and Head of the Molecular Therapeutics Section in the Developmental Therapeutics Branch of the Center for Cancer Research before moving to Columbia University in August 2015. During her years at the NCI, Dr. Bates led a highly successful translational research program focused on mechanisms of multidrug resistance and approaches to evaluate and improve the activity of epigenetic modifying agents. Her laboratory was among the first to clone the multidrug transporter ABCG2, eventually characterizing its function and its role in chemo-resistance and chemo-protection. This effort built upon earlier work elaborating the role of the multi-drug transporter P-glycoprotein that had defined the drug sensitivity profiles of cell lines in vitro, particularly in the NCI-60 cell line panel. The latter observation continues to impact how the NCI-60 cell line panel is used in drug discovery, and helped her identify a novel agent, at that time known as depsipeptide. Dr. Bates brought this drug to the clinic and after completing its phase I testing, served as Principal Investigator of a multi-institutional, international Phase II study of romidepsin (depsipeptide) in cutaneous and peripheral T-cell lymphoma. Working with Gloucester Pharmaceuticals, the data from this study were included in New Drug Applications (NDA) to the U.S. Food & Drug Administration (FDA). This partnership led to approval by the FDA of romidepsin for two indications - initially for cutaneous T-cell lymphoma and later for peripheral T-cell lymphoma. Dr. Bates' current interests are both laboratory and clinical in nature. Her laboratory efforts include laboratory and translational studies on drug resistance in T-cell lymphomas and advanced solid tumors including breast, pancreatic, neuroendocrine, renal and lung cancers. Her work is dedicated to new drug development, and finding antineoplastic agents that, alone or in combination with other anticancer agents, improve the options available for difficult to treat cancers. Emanating from the clinical and translational development of romidepsin, a histone deacetylase (HDAC) inhibitor, a current focus is on epigenetic therapies, and the development of combination therapies to use with HDAC inhibitors in refractory advanced cancers, including solid tumors. She also has a special interest in drug delivery and drug distribution and the role of the blood brain barrier in creating a sanctuary site for cancers that metastasize to the brain. Clinically, her goal has always been to translate ideas from the laboratory to clinical trials, an effort that has proven very successful. Clinically she seeks to develop combination therapies with histone deacetylase inhibitors for the therapy of solid tumors; and to develop therapies to treat central nervous system metastases, a complication of cancer that is becoming a greater problem as patients live longer with cancer.
Click or call for more information

Also at this address

Owner verified
See a problem?

You might also like

Katherine Fischkoff, MD
Internal medicine practitioners, Services, nec, nec

Katherine Fischkoff, MD

Katherine Fischkoff, MD is a general and acute care surgeon, with a special interest in medical ethics. Dr. Fischkoff’s clinical skills and research expertise have earned her recognition as Medical Director for the Surgical Step Down Unit and Vice-Chair of the Department of Surgery’s Quality and Patient Safety Committee. She has produced influential research in the field of medical ethics to help clarify the role of the surgeon in difficult ethical situations. During the COVID pandemic, she led the way in developing standard-of-care recommendations to guide the diverse and numerous ethics challenges faced by all healthcare workers. Dr. Fischkoff earned her medical degree from George Washington University and went on to receive specialized training at NYU, Cornell and Memorial-Sloan Kettering before joining the team at Columbia.
Lisa S. Wiechmann, MD
Internal medicine practitioners

Lisa S. Wiechmann, MD

Dr. Wiechmann is a board certified surgeon specializing in breast cancer, who was recognized with honors by the Breast Cancer Alliance, the Susan G. Komen for the Cure foundation and the Society of Surgical Oncology. Dr. Wiechmann's dedication to patient-driven, personalized care has earned many awards. These include the “Faces of Respect” Award at Montefiore Medical Center (2011-2013) and the Greenwich Hospital Quality Award (2015). Her peers recently selected Dr Wiechmann as a Castle Connolly Top Doctor, a nationally ranked service whose mission is to help consumers find the best healthcare; she has been listed in the “Guide to America’s Top Surgeons” for the past 3 years. Dr. Wiechmann is a breast surgeon with over 10 years of experience at the Comprehensive Breast Center of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, a multi-site, multi-disciplinary entity that incorporates the legacy of innovation and trust associated with the Columbia University Irving Medical Center. She works closely with a multi-disciplinary team including radiologists, medical oncologists, radiation oncologists, plastic surgeons and other breast cancer support staff. Her goal is to make patient and family experience as simple, thorough, and streamlined as possible. Dr Wiechmann approaches each patient in a personal, kind, and compassionate way and believes in shared decision-making and teamwork. She speaks English, Spanish, and Italian fluently and can conduct the consultation in any of those languages. In the clinic, Dr. Wiechmann's interests include triple negative breast cancer (ER, PR, and HER2 negative), the genetic and familial predisposition to breast cancer, and disparities in cancer treatment and outcomes. Dr Wiechmann, who was born and raised in Florence, Italy, received her medical degree Magna Cum Laude at Universita' Degli Studi Di Firenze Facolta' Di Medicina e Chirurgia in Florence, Italy. She completed a General Surgery Residency at TUFTS, St. Elizabeth's Medical Center in Boston followed by a research fellowship in the prestigious laboratory of Dr Kent Osborne and Dr Rachel Schiff, at the Lester and Sue Smith Breast Center of the Dan L. Duncan Cancer Center at Baylor College of Medicine, in Houston, Texas. At Baylor, her research focused on the preclinical development of therapies targeting the HER2 receptor; her work was recognized by Komen/AACR. Dr Wiechmann’s work has been published in many surgical and the Breast Cancer Alliance, the Susan G. Komen for the Cure foundation and the Society of Surgical Oncology have repeatedly recognized oncology publications and her with awards for her research and scholarship. After completing her research at Baylor, Dr Wiechmann was the recipient of the Breast Cancer Alliance award that funded her clinical fellowship at Memorial Sloan-Kettering Cancer Center, which led to her participation in the prestigious ASCO/AACR (American Society for Clinical Oncology/American Association for Cancer Research) course, Methods in Clinical Cancer Research.
Antonio Tito Fojo, MD
Internal medicine practitioners

Antonio Tito Fojo, MD

Dr. Fojo received his MD and PhD from the University of Miami and completed internal medicine training at Washington University School of Medicine / Barnes Hospital. He joined the National Cancer Institute in 1982 as a Clinical Associate in the Medicine Branch and after training with Drs. Ira Pastan and Michael Gottesman, became a Principal Investigator in the Medicine Branch of the National Cancer Institute. As a Principal Investigator he went on to establish a highly successful translational clinical program that began by exploring agents to reverse drug resistance, continued with work on the optimal use of Taxol®, and the development of novel microtubule-targeting agents and has focused on the development of therapies for endocrine and neuroendocrine cancers. Dr. Fojo has expertise in the management of patients with adrenocortical cancer, malignant pheochromocytoma and other neuroendocrine malignancies, and thyroid cancer. These cancers also comprise areas of very active basic science interest given their unique properties and the possibilities to target such cancers more precisely. The ultimate goal is to develop novel therapies for these often very refractory cancers so that there will be additional options available for treatment for patients with these cancers. Ongoing laboratory efforts are focused on developing such novel therapies to treat patients with adrenal cancer, pheochromocytoma and a spectrum of neuroendocrine tumors. In the laboratory Dr. Fojo has also worked to understand the molecular basis of drug resistance, and was involved in the original work relating to several ABC transporters. Additionally, his laboratory originally identified rearrangements involving the MDR-1 gene as a novel mechanism of drug resistance in several cancers, a molecular event recently demonstrated as very important in ovarian cancer. He has also been very involved in research on microtubule-targeting agents, helping to establish as a novel paradigm the interference with microtubule trafficking, rather than mitosis, for the mechanism of action for these important drugs. In addition to his clinical expertise Dr. Fojo has been very interested in the design, conduct and interpretation of oncology clinical trials and in collaboration with Wilfred Stein, PhD and Susan Bates, MD has helped to pioneer a novel method of analysis that dissects rates of tumor growth and regression as concurrent events. Related to this he has also written extensively about the cost of cancer therapeutics, the magnitude of the problem and how this might be addressed. Dr. Fojo served as Program Director for the Medical Oncology Fellowship Program at the National Cancer Institute, the largest fellowship program in the NIH and one of the largest medical oncology programs in the United States. Over the years Dr. Fojo has helped to train more than 350 medical oncologists.
United States›New York›New York›Susan E. Bates, MD

Partial Data by Infogroup (c) 2025. All rights reserved.

Yext

Partial Data by Foursquare.